Combined-modality 125J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects

Boehle, Andreas; Katic, Katharina; König, Inke R.; Robrahn-Nitschke, Irina; Renner, Peter; Brandenburg, Bernd

doi:10.1007/s00345-019-02649-2

Cited by 4 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…60.7% and 39.3% of patients were attributable to intermediate-and high-risk groups, respectively. Patient characteristics are shown in Table 1, and further details of the whole cohort have been published elsewhere (14).…”

Section: Resultsmentioning

confidence: 99%

“…Intraoperative and 6-week postoperative radiation doses were documented for quality control as proposed by Stock (13) and are reported elsewhere (14).…”

Section: Methodsmentioning

confidence: 99%

“…Results of treatment-related toxicity are reported elsewhere (14). The Kaplan-Meier product-limit method and the logrank test were applied to estimate survival probabilities and compare survival, respectively.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy

et al. 2020

View full text Add to dashboard Cite

PURPOSE: To compare a standard radio-oncological and a surgical biochemical failure definition after combined-modality radiation therapy (CRT) in men with intermediate-and high-risk prostate cancer. METHODS: 425 men were treated with external beam radiotherapy (59.4 Gy, 33 fractions) and 125 J seed-brachytherapy (S-BT, 100 Gy). Biochemical recurrence (BR) was defined either as radio-oncologic (rBR), using a þ2 ng/mL prostate-specific antigen (PSA) increase above a nadir value, or as surgical (sBR), using a 2-year posttreatment PSA of $0.2 ng/mL. Biochemical recurrence-free, metastasis-free, cancer-specific, and overall survival were calculated at 5 and 10 years using the Kaplan-Meier method. Standard validation tests were used to compare both thresholds. RESULTS: After a median of 7 years, overall recurrence rates were 10.4% and 31.5% for rBR and sBR definitions, respectively. Both failure definitions proved sensitive for the prediction of metastases and cancer-specific death, whereas the rBR definition was significantly more specific. The accuracies of a correct prediction of metastases and death of prostate cancer were 73.1% vs. 96.2% and 72.2% vs. 92.9% for sBR vs. rBR, respectively. The inferior validity results of the sBR definition were attributable to a PSA-bounce phenomenon occurring in 56% of patients with sBR. Still, using the less suitable sBR definition, the results of CRT compared favorably to BRFS rates of surgical interventions. CONCLUSION: After CRT, the radio-oncological (aka Phoenix) failure definition is more reliable than a fixed surgical endpoint. Exclusively in high-risk patients, sBR offers a direct comparison across surgical and nonsurgical treatment options at 5 and 10 years.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Intraoperative and 6-week postoperative radiation doses were documented for quality control as proposed by Stock (13) and are reported elsewhere (14).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Patient data were recorded independently at each institution, anonymized, and entered into a shared database as described recently. 10 …”

Section: Methodsmentioning

confidence: 99%

“… 3 , 4 , 15 , 16 Intraoperative and 6 week–postoperative radiation doses were documented for quality control as proposed by Stock and Stone 15 and are reported elsewhere. 10 , 17 All involved institutions provided independent follow-up. Follow-up visits were appointed every 3 months for 2 years, every 6 months for another 2 years, and yearly thereafter.…”

Section: Methodsmentioning

confidence: 99%

Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?

Boehle

Zywietz²,

Robrahn-Nitschke³

et al. 2023

Advances in Radiation Oncology

Self Cite

View full text Add to dashboard Cite

LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients

Boehle,

Zywietz,

Robrahn-Nitschke

et al. 2023

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Combined-modality 125J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects

Cited by 4 publications

References 32 publications

Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy

Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy

Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?

LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients

Contact Info

Product

Resources

About